Table 1 Patient characteristics
From: Operative invasiveness does not affect the prognosis of patients with non-small cell lung cancer
Gender (male / female) | 281 (61%) / 182 (39%) |
Age (y.o.), median (range) | 68.4 (34–87) |
Smoking index, median (range) | 600 (0–3600) |
CEA (ng/ml), median (range) | 3.6 (0.5–236) |
Charlson comorbidity index (0 / 1 / 2 / 3 / 4) | 282 (61%) / 108 (23.2%) / 62 (13.4%) / 9 (2%) / 2(0.4%) |
Wound length (cm), median (range) | 8 (3–25) |
Approach (C-VATS / Hybrid / Thoracotomy) | 77 (17%) / 321 (69%) / 65 (14%) |
Operative procedure (Seg / Lob / Bilob / Pneumo) | 26 (6%) / 409 (88%) / 10 (2%) / 18 (4%) |
Operation time (min), median (range) | 230 (67–674) |
Histology (Ad / Sq / AdSq / LCNEC / Large / Pleo) | 350 (76%) / 91 (19.6%) / 8 (1.6%) / 9 (1.8%) / 3 (0.6%) / 2 (0.4%) |
Differentiation (G1 / 2 / 3 / 4) | 173 (37.4%) / 203 (43.8%) / 75 (16.2%) / 12 (2.6%) |
Ly (0 / 1) | 271 (58.5%) / 192 (41.5%) |
V (0 / 1) | 236 (51%) / 225 (49%) |
pStage (IA / IB / IIA / IIB / IIIA) | 225 (48.5%) / 101 (21.8%) / 48 (10.4%) / 43 (9.3%) / 46 (10%) |
Preoperative CRP (ng/ml), median (range) | 0.1 (0.02–14.89) |
Postoperative CRP (ng/ml), median (range) | 13.39 (0.66–36.28) |
Clavien-Dindo grade (0 / 1 / 2 / 3a / 3b) | 340 (73.4%) / 20 (4.3%) / 45 (9.7%) / 53 (11.4%) / 5 (1.2%) |